Back to Search Start Over

p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.

Authors :
Taylor W
Mathias A
Ali A
Ke H
Stoynev N
Shilkaitis A
Green A
Kiyokawa H
Christov K
Taylor, Winna
Mathias, Amanda
Ali, Arshia
Ke, Hengning
Stoynev, Nikolay
Shilkaitis, Anne
Green, Albert
Kiyokawa, Hiroaki
Christov, Konstantin
Source :
BMC Cancer; 2010, Vol. 10, p541-541, 1p
Publication Year :
2010

Abstract

<bold>Background: </bold>p27 is a cell cycle suppressor gene, whose protein is a negative regulator of cyclin/cdk complexes. p27 is also a potential target of retinoids in cancer prevention studies. In benign prostate hyperplasia (BPH), and in most carcinomas, p27(Kip1) is down-regulated, suggesting its potential resistance to retinoids. To test this hypothesis, we examined the efficacy of 9-cis retinoic acid (9cRA) to suppress prostate cell proliferation (PECP) and carcinogenesis in p27(Kip1) deficient mice.<bold>Methods: </bold>p27(Kip1) deficient (-/-), heterozygous (+/-) and homozygous (+/+) mice were treated for 7 days with testosterone, 9cRA, or with both, and cell proliferation in dorsolateral prostate (DLP) was determined by BrdU labeling. Prostate carcinogenesis was induced by N-Methyl-N-Nitrosourea (MNU) and hormone stimulation.<bold>Results: </bold>PECP in DLP of two-month-old mice of all genotypes was similar but significantly increased in old p27-/- mice only. Testosterone treatment increased PECP in all three p27 genotypes with the highest values in p27-/- mice. p27(Kip1) deficiency did not affect the response of PEC to 9cRA and to 9cRA+testosterone. The decrease of p27(Kip1) in p27+/- and p27-/- mice progressively increased the incidence and frequency of PIN and tumors. 9cRA suppressed PIN in all three p27 genotypes and this was associated with decreased PECP and increased cellular senescence.<bold>Conclusions: </bold>This data indicates that p27(Kip1) deficiency promotes prostate cell proliferation and carcinogenesis but does not affect 9cRA's potential to suppress prostate carcinogenesis, suggesting that patients with PIN and carcinomas lacking or having a low level of p27(Kip1) expression may also benefit from clinical trials with retinoids. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712407
Volume :
10
Database :
Complementary Index
Journal :
BMC Cancer
Publication Type :
Academic Journal
Accession number :
104936059
Full Text :
https://doi.org/10.1186/1471-2407-10-541